Creative Biogene Qvirus Platform Releases Comprehensive Services to Support The Development of Gene Therapy
New York – Jul 23th, 2019 – Qvirus platform, which is established by Creative Biogene, offering a comprehensive portfolio of services for the efficient design, development, manufacturing and analytical testing of virus vector products. Recently, Qvirus platform launches its services that enable Creative Biogene an industry leader in supporting the development and GMP manufacture of viral vaccines, gene therapies, as well as other virus-based technologies.
Gene therapy is the intracellular delivery of genomic material (transgenic) into specific cells to produce a therapeutic effect by correcting existing abnormalities or providing new functions to the cells. At present, many types of gene delivery systems have been applied to gene therapy to restore specific gene functions or to shut down specific genes. The ultimate goal of gene therapy is to administer appropriate materials in order to replace defective or missing genes. One of the currently available successful gene therapy systems is a viral vector, such as a retrovirus, an adenovirus etc. Several viral vectors have been designed with specific receptors that can transfer the transgene to some other specific cell, Creative Biogene is capable to offer these viral vectors for researchers worldwide.
The use of RNAi interference to combat gene expression has been a particularly active area of research and has shown that many diseases, particularly those caused by viral infections and cancer, are sensitive to RNAi-mediated inhibition. The use of viral vectors can alleviate the inefficient delivery of in vivo in the synthesis of siRNA, the shortcomings of transient gene silencing. The ability of lentiviral vectors to integrate the production of proviral sequences of antiviral RNAi activators is particularly useful for the treatment of viral diseases caused by chronic infections.
Besides, CAR T cells have clinical efficacy in hematological malignancies and have a more modest response when targeting solid tumors. The main vector for gene therapy in basic research and clinical research is the virus, because the transfer efficiency is high, the time required to reach the clinically necessary number of cultured T cells is relatively short, and the availability of different viruses with different expression characteristics.
‘Our QVirus platform offers a variety of optimized viral vectors for wide application. Each virus has different characteristics and is, therefore, suitable for a specific research goal.’ said Marcia Brady, the marketing director of Creative Biogene, she also said that, ‘Building a viral vector is a laborious process, however, most commercial services in the field are too expensive, we have spent years of efforts to enable us offering cost-effective and high-quality services.’
About Creative Biogene Qvirus Platform
Qvirus Platform, as a division of Creative Biogene, providing world-class packaging services for a variety of virus vector products. The expertise and years of experience have made Qvirus platform become a well-recognized industry leader in supporting the development of gene therapy and scientists worldwide.
Media Contact
Company Name: Creative Biogene
Contact Person: Marcia Brady
Email: Send Email
Phone: 6316197922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: https://www.creative-biogene.com
